Cargando…

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

SIMPLE SUMMARY: The treatment of advanced and metastatic non-small cell lung cancer (NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics and the recognition of targetable oncogenic driver alterations. This has led to the development of very effective new targeted ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	König, David, Savic Prince, Spasenija, Rothschild, Sacha I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918961/ https://www.ncbi.nlm.nih.gov/pubmed/33671873 http://dx.doi.org/10.3390/cancers13040804

Ejemplares similares

Prädiktive Immunzytochemie beim nicht-kleinzelligen Lungenkarzinom
por: Brcic, Luka, et al.
Publicado: (2022)

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
por: Zhao, Yiming, et al.
Publicado: (2021)

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
por: Alborelli, Ilaria, et al.
Publicado: (2019)

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
por: Kim, So Yeon, et al.
Publicado: (2020)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
por: Mazieres, J., et al.
Publicado: (2019)

Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
por: Matter, Matthias S., et al.
Publicado: (2020)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild, Sacha I
Publicado: (2014)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
por: Cui, Jinfeng, et al.
Publicado: (2022)

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
por: König, David, et al.
Publicado: (2020)

Alterations of oncogenes in metastatic tumours of human gastric carcinomas.
por: Tsujino, T., et al.
Publicado: (1990)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers
por: Odri, Guillaume Anthony, et al.
Publicado: (2022)

Oncogenic drivers and mitochondrial dependency
por: Alvarez-Calderon, Francesca, et al.
Publicado: (2015)

Genomic evolutionary trajectory of metastatic squamous cell carcinoma of the lung
por: Krause, Arthur, et al.
Publicado: (2021)

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors
por: Crosby, Erika J., et al.
Publicado: (2021)

Risk factors for polyoma virus nephropathy
por: Prince, Olivier, et al.
Publicado: (2009)

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
por: Rothschild, Sacha I.
Publicado: (2015)

Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver
por: Domènech, Marta, et al.
Publicado: (2021)

Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors
por: Einstein, David J., et al.
Publicado: (2021)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

SB Driver Analysis: a Sleeping Beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors
por: Newberg, Justin Y, et al.
Publicado: (2018)

Oncogenic driver mutations in lung cancer
por: Luo, Susan Y, et al.
Publicado: (2013)

Importance of Drug Pharmacokinetics at the Site of Action
por: Rizk, ML, et al.
Publicado: (2017)

“Exercise induced asthma” is not always asthma
por: Kofler, Thomas, et al.
Publicado: (2018)

Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer
por: Chrisoulidou, Alexandra, et al.
Publicado: (2011)

Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers
por: Qiu, Luping, et al.
Publicado: (2018)

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
por: Legius, Barbara, et al.
Publicado: (2016)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma
por: Péneau, Camille, et al.
Publicado: (2022)

Regulation of assimilate import into sink organs: update on molecular drivers of sink strength
por: Bihmidine, Saadia, et al.
Publicado: (2013)

A case report of a cystic fibrosis patient with repeated isolation of Trichosporon mycotoxinivorans identified by a novel short-extraction method
por: Goldenberger, Daniel, et al.
Publicado: (2016)

The long tail of oncogenic drivers in prostate cancer
por: Armenia, Joshua, et al.
Publicado: (2018)

Oncogenic Viruses as Entropic Drivers of Cancer Evolution
por: Tempera, Italo, et al.
Publicado: (2021)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

The most important outcome
por: Clement, Elizabeth
Publicado: (2023)

CtBP- an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors
por: Dcona, M. Michael, et al.
Publicado: (2017)

Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine
por: Ruiz, Christian, et al.
Publicado: (2016)

Flavor and product messaging are the two most important drivers of electronic cigarette selection in a choice-based task
por: Baker, Allison N., et al.
Publicado: (2021)

Relationship of driver oncogenes to long term pemetrexed response in non-small cell lung cancer
por: Liang, Ying, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_brphpjd5nj0bdrh1hsootsb03p